glp 1 agonist fda approved for weight loss New GLP-1 Pill Foundayo (Orforglipron) Gets Approval Obesity Wegovy Pill Wins FDA Approval

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

We explore the underlying biological mechanisms, summarize clinical trial evidence, and highlight emerging applications in non-diabetic populations

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials

Summary GLP-1 RAs alter gastrointestinal motility at all levels of the GI tract, with delayed gastric emptying being the most well characterized

A mechanistic guide to this next-generation metabolic peptide.

Differences between GLP1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) ...